Development, qualification, and validation of the Filovirus Animal Nonclinical Group anti-Ebola virus glycoprotein immunoglobulin G enzyme-linked immunosorbent assay for human serum samples-Reference-Cited by-同舟云学术

Development, qualification, and validation of the Filovirus Animal Nonclinical Group anti-Ebola virus glycoprotein immunoglobulin G enzyme-linked immunosorbent assay for human serum samples

Published:2019-04-18 Issue:4 Volume:14 Page:e0215457
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Rudge Thomas L.^ORCID,Sankovich Karen A.,Niemuth Nancy A.,Anderson Michael S.,Badorrek Christopher S.,Skomrock Nick D.,Cirimotich Chris M.,Sabourin Carol L.

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference45 articles.

1. Emergence of Zaire Ebola virus disease in Guinea;S Baize;The New England journal of medicine,2014

2. Nomenclature- and database-compatible names for the two Ebola virus variants that emerged in Guinea and the Democratic Republic of the Congo in 2014;JH Kuhn;Viruses,2014

3. Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak;SK Gire;Science (New York, NY),2014

4. Fighting Ebola: A Window for Vaccine Re-evaluation?;KJ Chappell;PLoS pathogens,2017

5. Toward an Effective Ebola Virus Vaccine. Annual review of medicine;R Keshwara;Toward an Effective Ebola Virus Vaccine. Annual review of medicine,2017

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Replication, safety and immunogenicity of the vectored Ebola vaccine rVSV-ΔG-ZEBOV-GP in a sub-Saharan African paediatric population: A randomised controlled, open-label trial in children aged 1-12 years living in Lambaréné, Gabon;Journal of Infection;2024-10

2. Knowledge, attitudes, and practices and long-term immune response after rVSVΔG-ZEBOV-GP Ebola vaccination in healthcare workers in high-risk districts in Uganda;Vaccine;2024-09

3. Immunogenicity of an Extended Dose Interval for the Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen in Adults and Children in the Democratic Republic of the Congo;Vaccines;2024-07-23

4. Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccine regimen plus Ad26.ZEBOV booster at 1 year versus 2 years in health-care and front-line workers in the Democratic Republic of the Congo: secondary and exploratory outcomes of an open-label, randomised, phase 2 trial;The Lancet Infectious Diseases;2024-07

5. Lot-to-lot consistency, immunogenicity, and safety of the Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccine regimen: A phase 3, randomized, double-blind, placebo-controlled trial;Human Vaccines & Immunotherapeutics;2024-03-24